Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neupath Health Inc. ( (TSE:NPTH) ) has issued an update.
NeuPath Health Inc. reported record 2025 results, with fourth-quarter revenue rising 17% year over year to $22.1 million and full-year revenue up 20% to $87.2 million, driven largely by higher patient volumes, the launch of Arthrosamid and stronger fluoroscopy revenues. Adjusted EBITDA increased 9% in the quarter and 56% for the year to $6.0 million, while the company ended 2025 with $4.5 million in cash and $6.2 million in long-term debt, positioning incoming CEO Stephen Lemieux to pursue further growth, margin improvement and geographic expansion in 2026.
Clinic revenue climbed to $20.7 million in the quarter and $81.8 million for the year, supported by improved capacity utilization and a one-time physician reimbursement adjustment, while non-clinic revenue held roughly flat at $5.4 million annually. Although gross margin percentage remained steady at 19.0% for the year and edged slightly lower in the fourth quarter, NeuPath logged its 28th consecutive quarter of positive adjusted EBITDA, reinforcing its standing in Canada’s pain management market as it broadens access to innovative procedures such as Arthrosamid and prepares for leadership transition.
The most recent analyst rating on (TSE:NPTH) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Neupath Health Inc. stock, see the TSE:NPTH Stock Forecast page.
More about Neupath Health Inc.
NeuPath Health Inc. operates one of Canada’s largest networks of community-based, multidisciplinary medical clinics focused on chronic pain, musculoskeletal and back pain, sports medicine and related pain services. The Toronto-based company also generates non-clinic revenue by supplying physicians to correctional institutions across Canada and providing contract research services to pharmaceutical firms and clinical research organizations.
Average Trading Volume: 87,303
Technical Sentiment Signal: Buy
Current Market Cap: C$26.11M
For an in-depth examination of NPTH stock, go to TipRanks’ Overview page.